<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036200</url>
  </required_header>
  <id_info>
    <org_study_id>19-065</org_study_id>
    <nct_id>NCT05036200</nct_id>
  </id_info>
  <brief_title>Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma</brief_title>
  <acronym>PDL</acronym>
  <official_title>Efficacy, Tolerance and Acceptability of Pulsed Dye Laser on Telangiectasias of the Face and Neckline in Systemic Scleroderma: a Prospective Single-center Open-label Study of 21 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, prospective, open-label, quasi-experimental, intra-individual comparative&#xD;
      study will include a consecutive cohort of 21 patients with diffuse or limited, minimally&#xD;
      active scleroderma with 3 to 30 years of evolution.&#xD;
&#xD;
      Patients will have 4 sessions of pulsed dye laser 595 nm spaced 8 weeks apart. The final&#xD;
      quadruple evaluation by several evaluators will be 2 months after the last session, on the&#xD;
      following criteria: evolution of the number of telangiectasia; subjective improvement score&#xD;
      (LINKERT scale); impact on quality of life (SKINDEX score); visual analog pain scale (VAS);&#xD;
      adverse events (AEs), including discontinuation of treatment due to post-session purpura&#xD;
      (AT-PPS); patient satisfaction (yes or no).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To evaluate the efficacy of pulsed dye laser treatment on facial and neckline telangiectasias&#xD;
      in systemic scleroderma by comparing the mean number of telangiectasias.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Evaluation of the aesthetic efficacy by the patient, observer and adjudication committee&#xD;
      Evaluation of the impact on the quality of life after treatment (skindex) Evaluation of&#xD;
      treatment tolerance in terms of pain (VAS) and adverse events (purpura, oozing,&#xD;
      hyperpigmentation, hospitalization)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the decrease in the number of telangiectasia</measure>
    <time_frame>baseline and two months after last intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life after pulsed dye laser treatment using the SKINDEX questionnaire</measure>
    <time_frame>baseline and two months after last intervention</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>evaluation of the aesthetic improvement with an improvement score scored using a LIKERT scale from -1 to +2: from -1= worse; 0= unchanged ; +1= improved ; +2= much improved</measure>
    <time_frame>baseline and two months after last intervention</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Telangiectasia</condition>
  <arm_group>
    <arm_group_label>four pulsed dye laser sessions were administered every eight weeks in the 21 patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pulsed dye laser</intervention_name>
    <description>four pulsed dye laser sessions were administered every eight weeks in the 21 patients</description>
    <arm_group_label>four pulsed dye laser sessions were administered every eight weeks in the 21 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient followed in dermatology and/or internal medicine at the University Hospital of&#xD;
             Caen for systemic scleroderma&#xD;
&#xD;
          -  patient with telangiectasias related to scleroderma&#xD;
&#xD;
          -  patient with an aesthetic prejudice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with previous laser treatment for facial telangiectasias.&#xD;
&#xD;
          -  Tanned, irritated or traumatized facial skin&#xD;
&#xD;
          -  Patient not affiliated to the Social Security system&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Caen Normandie</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Mayo TT, Khan F, Hunt C, Fleming K, Markus R. Comparative study on bruise reduction treatments after bruise induction using the pulsed dye laser. Dermatol Surg. 2013 Oct;39(10):1459-64. doi: 10.1111/dsu.12293. Epub 2013 Jul 30.</citation>
    <PMID>23899131</PMID>
  </reference>
  <reference>
    <citation>Yalcinkaya Y, Pehlivan O, Omma A, Alpay N, Erer B, Kamali S, Ocal L, Inanc M. The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis. Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S92-7. Epub 2015 Mar 23.</citation>
    <PMID>25797836</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

